多发性骨髓瘤相当专业的ppt NCCN-MM+2010-CH

Version 2.2010, 07/01/09 © 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN

NCCN 多发性骨髓瘤专家组

Kenneth C. Anderson, MD/Chair ‡ Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Melissa Alsina, MD ‡

H. Lee Moffitt Cancer Center & Research Institute

William Bensinger, MD †

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance J. Sybil Biermann, MD ¶

University of Michigan Comprehensive Cancer Center

Asher Chanan-Khan, MD † Roswell Park Cancer Institute

Raymond L. Comenzo, MD‡ Þ

Memorial Sloan-Kettering Cancer Center Steven Devine, MD†

Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at the Ohio State University

Benjamin Djulbegovic, MD , PhD † ‡

H. Lee Moffitt Cancer Center & Research Institute

Cristina Gasparetto, MD †

Duke Comprehensive Cancer Center

Carol Ann Huff, MD †

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Madan Jagasia, MD ‡

Vanderbilt-Ingram Cancer Center Bruno C. Medeiros, MD ‡

Stanford Comprehensive Cancer Center Ruby Meredith, MD, PhD §

University of Alabama at Birmingham Comprehensive Cancer Center

Rajneesh Nath, MD ‡

St. Jude Children's Research

Hospital/University of Tennessee Cancer Institute

Noopur Raje, MD † ‡

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center Jeffrey Schriber, MD ‡ City of Hope

Dennis Shrieve, MD, PhD §

Huntsman Cancer Institute at the University of Utah

Seema Singhal, MD ‡

Robert H. Lurie Comprehensive Cancer Center of Northwestern University Mitchell R. Smith, MD, PhD † ‡ Fox Chase Cancer Center

George Somlo, MD † ‡ Þ City of Hope

Keith Stockerl-Goldstein, MD †

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Guido Tricot, MD, PhD ‡

Huntsman Cancer Institute at the University of Utah

Julie M. Vo se, MD ‡

UNMC Eppley Cancer Center at the Nebraska Medical Center

Donna Weber, MD † ‡ Þ

The University of Texas M. D. Anderson Cancer Center

Joachim Yahalom, MD §

Memorial Sloan-Kettering Cancer Center

Version 2.2010, 07/01/09 © 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN

目录

NCCN 多发性骨髓瘤专家组 如需使用这些文件的帮助， 请点击此处 指南更新内容概要 多发性骨髓瘤：

● 初诊检查和临床表现（MYEL-1）

● 骨或骨外孤立性浆细胞瘤：基础治疗（MYEL-2） 讨论 ● 多发性骨髓瘤：诱导治疗及随访（MYEL-3） 参考文献 ●

随访和监测（MYEL-4）

●

活动性疾病：疾病进展的新增治疗（MYEL-6） ●

多发性骨髓瘤的分期系统（MYEL-A ）

● 多发性骨髓瘤的定义（冒烟型和活动性骨髓瘤）（MYEL-B ） 临床试验：NCCN 认为任何肿瘤患者都可以在临床试验中得到最佳处理，因此特别鼓励肿瘤患者参加临床试验研究。 NCCN 成员单位临床试验在线查询，请点击： /clinical_trials/physician.html

NCCN 对共识的分类：除非特别说明，NCCN 对所有建议均达成2A 类共识。 参见NCCN 共识分类

● 多发性骨髓瘤的疗效评价标准（MYEL-C ） ● 诱导治疗（MYEL-D ） ● 辅助治疗（MYEL-E ）

●

系统性轻链型淀粉样变性（AL-1） Waldenstrom 巨球蛋白血症：

● 检查和基础治疗（WALD-1） ●

监测和随访（WALD-2）

指南索引

打印多发性骨髓瘤指南

作为共识，NCCN 肿瘤学临床指南反映了作者们对目前认可的治疗方法的观点。欲参考或应用这些指南的临床医师应根据每个具体的临床情况做出独立的医疗判断，来决定患者所需的治疗和护理。NCCN 对指南内容、用途或应用不做任何陈述或保证，也不对指南任何形式的应用或应用结果承担责任。版权所有。 如果没有NCCN 明确表述的书面许可，任何机构不得以任何方式应用指南及其图表。